The continued impairments taken as assets are explained as non-cash, which is of course true if you ignore that they used cash or other assets to purchase the asset. It didnt just magically appear on the balance sheet. '
Management #$%$ away their cash position on value destroying M&A is, to me, the number one risk for this stock and unfortunately is becoming very real. A classic value trap.
This one had me reading the financial definition of impairments to good will etc. WOW ! However., GRVY said it will make no difference to its EPS.
Only thing I learned is., "All things have value .. except stock."
No adjusted EPS impact. This will certainly impact earnings, but similar to calling it non-cash they will adjust it out. I think they will end the year with close to $15m in impairment charges, which is almost half their market cap in bad investments and we wonder why they trade at a discount to cash.